Uncategorized

Lilly, Baseline Investigate GLP-1s’ Potential in Substance Use as Interest Mounts

Published

1 week ago

on

Accumulating scientific evidence and industry interest from Eli Lilly, Altimmune and startup Baseline Therapeutics is driving further research on the therapeutic potential of GLP-1 receptor agonists in treating substance use disorders.

Related Topics:

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version